HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cunnien, A. J. Articles by Scanlon, P. W. Search for Related Content PubMed PubMed Citation Articles by Cunnien, A. J. Articles by Scanlon, P. W.

Radioiodine-Induce Hypothyroidism in Graves' Disease: Factors Associated with the Increasing Incidence

Mayo Clinic and Mayo Foundation, Rochester, Minnesota

Correspondence: For reprints contact: Alan J. Cunnien, M.D., c/o Section of Publications, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.

ABSTRACT

A retrospective analysis was done of the records of 454 patients who received their first I-131 treatment for Graves' disease during six periods covering 1951 to 1978. In the earliest group, 3% of patients were hypothyroid 3 mo after I-131 use, and 40% were hypothyroid at 1 yr. In the most recent group, 36% of patients were hypothyroid at 3 mo and 91% were myxedematous at 1 yr. Although no obvious trends were noted, whether in the number of patients pretreated with thionamide drugs, in the mean 24-hr I-131 uptake, or in the calculated dose of I-131 (µCi/estimated gram of thyroid tissue) during the years of the study, the initial mean dose of I-131 administered increased from 8.1 mCi in the earliest group to 13.8 mCi in the latest group. Concurrently, estimates of gland size increased from a mean of 26 g in the first group to 43 g in the last. If, in patients with Graves disease, the thyroid gland size did not truly increase during the years of the study, the increasing occurrence of early hypothyroidism seen after I-131 use may reflect the conscious or unconscious decision to use larger doses of I-131 calculated on the basis of inflated estimates of thyroid gland weight.

This article has been cited by other articles:

				J. E. Kalinyak and I. R. McDougall How Should the Dose of Iodine-131 Be Determined in the Treatment of Graves' Hyperthyroidism? J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 975 - 977. [Full Text] [PDF]

				F. Bogazzi, L. Bartalena, A. Campomori, S. Brogioni, C. Traino, F. De Martino, G. Rossi, F. Lippi, A. Pinchera, and E. Martino Treatment with Lithium Prevents Serum Thyroid Hormone Increase after Thionamide Withdrawal and Radioiodine Therapy in Patients with Graves' Disease J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4490 - 4495. [Abstract] [Full Text] [PDF]

				E. K. Alexander and P. R. Larsen American Board of Internal Medicine. 2002 Certification Examination in Endocrinology, Diabetes, and Metabolism J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1073 - 1077. [Abstract] [Full Text] [PDF]

				V. A. Andrade, J. L. Gross, and A. L. Maia The Effect of Methimazole Pretreatment on the Efficacy of Radioactive Iodine Therapy in Graves' Hyperthyroidism: One-Year Follow-Up of a Prospective, Randomized Study J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3488 - 3493. [Abstract] [Full Text] [PDF]

				S. A. Rivkees, C. Sklar, and M. Freemark The Management of Graves' Disease in Children, with Special Emphasis on Radioiodine Treatment J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3767 - 3776. [Full Text]